Lactobacillus Helveticus Strain Composition for Inflammatory Bowel Disease

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for a safe and effective therapeutic agent for inflammatory bowel disease that does not have the side effects associated with existing treatments, and current probiotics have not reached commercial success in addressing this condition.

Innovation Solution

A Lactobacillus helveticus strain (Accession No. KCTC 14110BP) is developed, which can be used in pharmaceutical, food, and feed compositions, or administered directly to alleviate symptoms of inflammatory bowel disease without side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If sulfasalazine is used to treat inflammatory bowel disease, then therapeutic effect is achieved, but side effects such as nausea, vomiting, anorexia, headache, and anemia occur

Engineering Contradiction:

Improvetherapeutic effectVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the therapeutic agent from a chemical drug (sulfasalazine) to a biological agent (Lactobacillus helveticus strain MG585), fundamentally altering the treatment parameter from pharmacological to probiotic-based therapy. This strain-specific selection with deposited accession number KCTC 14110BP provides therapeutic efficacy while eliminating the harmful side effects associated with conventional medication.

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If existing probiotics are used for inflammatory bowel disease, then safety is improved, but therapeutic efficacy has not reached commercial success level

Engineering Contradiction:

ImprovesafetyVSAvoidtherapeutic efficacy

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent applies local quality by selecting a specific strain (Lactobacillus helveticus MG585) with particular characteristics optimized for inflammatory bowel disease treatment. Rather than using generic probiotics, this strain has been specifically identified and deposited (KCTC 14110BP) with enhanced therapeutic properties while maintaining the safety profile of probiotic organisms.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent creates a standardized, replicable therapeutic solution by depositing the specific strain at KCTC 14110BP, enabling consistent copying and distribution of this effective probiotic strain across commercial applications, thereby achieving both safety and reliable therapeutic efficacy.

Inventive Principle:

Principle #26Copying

Data Source

PatentUS12472215B2Lactobacillus helveticus strain and composition containing same for prevention or treatment of inflammatory diseases

Publication Date: 2025.11.18 GI BIOME INC

AI summary

Provided are a Lactobacillus helveticus strain and a composition for preventing or treating inflammatory disease containing the same. The Lactobacillus helveticus strain (Accession No. KCTC 14110BP) according to the present invention alleviates symptoms of inflammatory bowel disease, such as weight loss and bowel length reduction, and it does not have side effects that have been seen with existing drug treatment. Therefore, the Lactobacillus helveticus strain can be effectively used for the treatment and prevention of inflammatory disease, particularly inflammatory bowel disease.